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interested in this subject, through the maze
of information on industrial carcinogens and
mutagens is undisputed. The idea behind the
chapters and general layout of this volume is
good. The first 3 chapters introduce the
reader to the subject and outline some of the
problems posed by chemical interactions,
metabolism, risk assessment, epidemiology
and thresholds. The 4th chapter is a tabular
summary ofmutagenicity and carcinogenicity
data on 110 compounds. The remaining
chapters review information on production,
synthetic route, use and mutagenicity and
carcinogenicity data for 176 compounds. The
tabular summary and subsequent chapters
are arranged by chemical structure.
Unfortunately the excellent idea of a sum-
mary of this crucial information is not
carried through to the content. The first 3
introductory chapters appear to be a collage
of published views without any presentation
of the underlying hypotheses. The bases of
some of the major disagreements in the field
are not presented and, as a consequence, a
perplexing presentation of unsubstantiated
opinions results. The reader who does not
have a fairly extensive knowledge of this
subject will find this presentation confusing.
A second substantial criticism of this volume
is the extraordinary number oftypographical
and factual errors in every chapter. To check
all the facts presented is outside the scope of
the reviewer's task. The uninformed reader
is likely to be misled by these errors and even
the scientist working in the field is unable to
substantiate the tabular data in Chapter 4, as
there are no references. These errors are so
numerous that they will limit the usefulness
of the volume as a reference book.
I. F. H. PURCHASE
Immunotherapy of Human Cancer. (1978)
New York: Raven Press. 448 pp. $48-50.
The proceedings of a Symposium held at
the M. D. Anderson Hospital, this book
swells the ranks of recently published books
about human tumour immunotherapy. The
introduction by Drs Clark, Hickey and Hersh
contains the key to its understanding. At the
M. D. Anderson Hospital, we are told, there
are 20 immunotherapy trials in progress,
involving severalthousand patients. Immuno-
therapy is claimed to be the 4th major
modality of cancer treatment. Presumably
they believe that its value is as established as
the other 3. It works, they say, in acute
leukaemia, soft tissue and osteogenic sar-
comas, in malignant melanoma, gynaecologi-
cal and urogenital cancers, colorectal, breast
and lung tumours. Such an enthusiastic
introduction does not augur well for a rational
objective analysis of the topic.
The conference opens with a Heath
Memorial Award lecture by Professor Georges
Mathe, whose enthusiasm for immunotherapy
remains similarly unscathed. The rest of the
conference is logical, in form ifnot in content.
Four chapters examine the rational basis for
immunotherapy. Drs Fahey, Weiss and Fidler
present cautious but comprehensive essays,
examining in detail some mechanisms of host
resistance and how they might be mani-
pulated. The subsequent chapter on the
clinical reasons for trying immunotherapy,
by Dr Evan Hersh and 13 others, displays no
such caution and makes a variety of state-
ments that do not stand up to careful critical
examination. The main themes of their
argument are that (a) there is abundant
evidence for the immunogenicity of human
tumours and (b) that cancer patients are
immunodeficient. The evidence presented to
support these bold assertions, and therefore
the likely value of immunotherapy, is far
from convincing.
Starting the next section, on approaches
to immunotherapy, Dr David Weiss con-
tributes another valuable chapter about
animal models, the best thing in the book. It
is full of wit, erudition and objectivity. He
emphasizes the "distance between supposition
and reality" in transferring animal data to
human problems and roundly and rightly
condemns most of the animal model systems
in current use throughout the world.
The subsequent chapters describe the use of
exactly those models most devastatingly
criticised in Dr Weiss's essay. The use of
BCG and various extracted glycolipids,
Corynebacteria, thymosin, Levamisole, trans-
fer factor and isolated tumour "antigens" are
all in turn extolled. Dr Hollinshead's essay,
describing the latter, also tells us that high-
dose methotrexate works in lung cancer as a
form of immunotherapy because of rebound
overshoot! This is rather like banging your
head against a brick wall as a good treatment
for headache on the grounds that it feels good
once you stop.
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we are told about the successes (or likely
successes) of immunotherapy in most forms
of cancer. Professor Mathe, this time with
19 co-authors, tells us again of the value of
immunotherapy in ALL, and James Holland
does the same in AML more cautiously.
Others provide enthusiastic reports about
most other forms of cancer. Unfortunately
the only chapter which describes objective
evidence ofbenefit from a properly controlled
trial is that by Martin McKneally whose lung
cancer trial remains about the only success
which is not controversial (yet).
Pursuing its logical structure, the book
ends with 3 chapters about the prospects for
immunotherapy. They are optimistic, specu-
lative and have a familiar ring about them:
each could have been written 10 years ago.
Michael Mastrangelo and his colleagues are
the most rational, since they at least recognise
that immunotherapy is "relatively ineffec-
tual". These 3 chapters are depressing, since
in reviewing the prospects for this form of
treatment they exhibit a remarkable lack of
new ideas, reflecting perhaps a remarkable
lack of old ones.
The book ends not with a bang, but a
whimper. The final chapter by Dr Jordan
Gutterman is, as he says, a "call to arms".
His view ofthe prospects for immunotherapy
contains little science and is an attempt to
bolster enthusiasm for the topic. His excitable
brand of rhetoric would sound well on the
hustings or in a pulpit, but in a scientific
context has a hollow ring. He outlines and
promotes an approach to clinical science
which can only be described (complete with
split infinitive) as the Startrek principle: "to
boldly go where no man has gone before". To
support his theme, that we should regard
immunotherapy as a "good thing", he invokes
Benjamin Disraeli, Arthur C. Clarke, Thomas
Edison, Lord Rutherford, Jacob Bronowski,
Mendel, Darwin, Einstein, the British Navy,
God, Lewis Thomas (well, wrhy not?), Paul
Ehrlich, Fleming, Florey and Chain, Gunther
Grass, Robert Kennedy and an anonymous
Rabbi. These illustrious names are however
so much wallpaper. In the words of W. S.
Gilbert, if I may indulge in the same name-
dropping ploy, they are "merely corroborative
detail, intended to give artistic verisimilitude
to an otherwise bold and unconvincing
narrative".
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This report begins with a short clear review
of the harmful health consequences of
smoking, supporting the text with tables,
figures, and references; compared with many
WHO reports there is frequent reference to
the literature in support of the points made.
There is a useful section on the economic
implications of tobacco, which spells out the
costs of smoking, discusses the role of taxa-
tion, and indicates the harm to a country's
economy that can stem from growing and
processing tobacco, due to the requirement
for a very large work-force in the peak
harvest periods, the discouragement of other
crops, the vast requirement for wood for
curing, which is helping to spread deserts, the
limited proportion ofthe crop that is exported
in most countries, and the small part played
in the balance of payments.
A chapter discusses smoking control,
identifying the objectives, the role of govern-
ment, and strategies at international and
national levels and in relation to key groups,
political and religious leaders, the health
professions and teachers.
A chapter on public information and
education programmes sets out in verygeneral
terms how these may be conducted; though
the need for evaluation is stressed, the chapter
did not document successful approaches.
More detail is provided in the next two
chapters, which cover the control of smoking
by legislation and restrictive measures, and
various measures to help individuals to stop
smoking. It is stated that the evidence from
countries who have implemented compre-
hensive smoking control programmes has
'been encouraging'; some of the difficulties of
helping individuals is discussed, and awarning
given about the past tendency for some to
report exaggerated claims for their methods
of control.
The report ends with a strongly worded set
ofrecommendations addressedtoallcountries.
In this country there has already been a hint
that the policy towards this health hazard
may be tightened (Lancet, 1979 i, 1415).
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